Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829107 | PMC |
| http://dx.doi.org/10.1016/j.jdcr.2020.12.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Guillain Barre Syndrome (GBS): a case report.
Int J Emerg Med
September 2025
Department of Anesthesia, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab.
Dig Liver Dis
September 2025
Division of Pediatric Gastroenterology and Nutrition, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel; The Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel; Cincinnati Children's Hospital Medical Center and the University of Cin
Background And Aims: The development of antibodies to infliximab (ATI) is a major challenge in pediatric inflammatory bowel disease (IBD). This real-world study aimed to identify predictors of ATI, evaluate strategies to overcome ATI, and compare the durability of continuing infliximab (IFX) versus switching to adalimumab (ADA) after ATI development.
Methods: We retrospectively analyzed 194 pediatric IBD patients treated with IFX from 2010 to 2024.
Adverse Reactions to Taxanes in Premedicated Cancer Patients: A Prospective Observational Study.
Cureus
August 2025
Department of Pharmacology, Amrita Institute of Medical Sciences and Research Center, Amrita Vishwa Vidhyapeetham, Kochi, IND.
Introduction: Taxanes, including paclitaxel, docetaxel, and cabazitaxel, are widely used anticancer agents that disrupt cell division by binding to microtubules, but are associated with significant adverse reactions, particularly infusion-related reactions (IRRs), such as flushing, urticaria, and respiratory symptoms. Despite premedication with steroids, antihistamines, and antiemetics per guidelines, taxane-induced side effects remain prevalent and can result in treatment delays or discontinuation, impacting patient outcomes. This study aimed to observe and document the incidence and spectrum of adverse reactions to taxanes among premedicated cancer patients to improve management and overall chemotherapy success.
View Article and Find Full Text PDFCase Report: Remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy.
Front Immunol
September 2025
Department of Rheumatology and Immunology, The First Hospital of China Medical University, China Medical University, Shenyang, Liaoning, China.
CAR-T cell therapy has been proven effective in various autoimmune diseases, with most studies utilizing lentiviral-transduced CAR-T cells. In recent years, retroviral vector-transduced CAR-T cells-characterized by a high positivity rate, stable cell lines, and lower plasmid requirements-have attracted increasing attention. This article presents a complex case of a patient with SLE combined with APS and TBIRS.
View Article and Find Full Text PDFEfficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study.
Front Immunol
September 2025
Department of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, China.
Objective: This study aimed to evaluate the efficacy and safety of obinutuzumab, a novel anti-CD20 monoclonal antibody, in patients with primary membranous nephropathy (pMN).
Methods: Fifty-five patients with pMN treated with obinutuzumab were respectively enrolled in this study. Clinical and immunological response, renal function and adverse events were assessed throughout the follow-up period between patients receiving obinutuzumab as initial therapy and alternative therapy.